MDDT has been working to improve the lives of those who suffer from movement disorders since 2013. Now, one short year later, their product TremorTek is moving forward with clinical trials. Tremor is a debilitating symptom that affects more than 10 million people worldwide, including those with Essential tremors. Tremor in the hands and arms make it difficult to do all sorts of fine motor tasks like drinking, eating, writing, and typing. MDDT has found that tremor patients are under-treated with current therapies, and that physicians need better tools to assess tremor severity and track patient progress.
Exciting developments have allowed new wearable technologies to be more accurate in hospital tremor analysis in order to provide clinical guidance in treating tremor patients with a promising investigational drug. Earlier clinical trials using our investigational (under Health Canada) TremorTek system (research only) have shown that with guidance from MDDT’s system, the investigational drug can help to reduce tremors in patients. This new hybrid therapy using TremorTek sensor technology to guide investigational drug treatments would be a first of its kind in the tremor medical field.
Their multi-site clinical trial in treating Essential Tremors is now online, and more information relating to the trial can be found on http://clinicaltrials.gov/ under the clinical trial number: NCT02207946. Essential Tremor clinical trial sites in Canada include Toronto and Halifax. Additional clinical trials will begin later this year in Toronto and Winnipeg.
